The Relationship Between Target Joints and Direct Resource Use in Severe Haemophilia

Overview

Journal Health Econ Rev

Publisher Biomed Central

Specialty Public Health

Date 2018 Jan 18

PMID 29340855

Citations 15

Authors

Jamie OHara

Shaun Walsh

Charlotte Camp

Giuseppe Mazza

Liz Carroll

Christina Hoxer

Lars Wilkinson

Affiliations

Soon will be listed here.

Abstract

Objectives: Target joints are a common complication of severe haemophilia. While factor replacement therapy constitutes the majority of costs in haemophilia, the relationship between target joints and non drug-related direct costs (NDDCs) has not been studied.

Methods: Data on haemophilia patients without inhibitors was drawn from the 'Cost of Haemophilia across Europe - a Socioeconomic Survey' (CHESS) study, a cost assessment in severe haemophilia A and B across five European countries (France, Germany, Italy, Spain, and the United Kingdom) in which 139 haemophilia specialists provided demographic and clinical information for 1285 adult patients. NDDCs were calculated using publicly available cost data, including 12-month ambulatory and secondary care activity: haematologist and other specialist consultant consultations, medical tests and examinations, bleed-related hospital admissions, and payments to professional care providers. A generalized linear model was developed to investigate the relationship between NDDCs and target joints (areas of chronic synovitis), adjusted for patient covariates.

Results: Five hundred and thirteen patients (42% of the sample) had no diagnosed target joints; a total of 1376 target joints (range 1-10) were recorded in the remaining 714 patients. Mean adjusted NDDCs for persons with no target joints were EUR 3134 (standard error (SE) EUR 158); for persons with one or more target joints, mean adjusted NDDCs were EUR 3913 (SE EUR 157; average mean effect EUR 779; p < 0.001).

Conclusions: Our analysis suggests that the presence of one or more target joints has a significant impact on NDDCs for patients with severe haemophilia, ceteris paribus. Prevention and management of target joints should be an important consideration of managing haemophilia patients.

Citing Articles

An assessment of burden associated with problem joints in children and adults with moderate or severe haemophilia A: analysis of the CHESS-Paediatrics and CHESS II cross-sectional studies.

McLaughlin P, De la Corte-Rodriguez H, Burke T, Nissen F, Aizenas M, Moreno K Orphanet J Rare Dis. 2025; 20(1):18.

PMID: 39806420 PMC: 11726912. DOI: 10.1186/s13023-024-03514-1.

Evaluating the Cost-Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B Treatment in the USA.

Sarker J, Tice J, Rind D, Walton S Appl Health Econ Health Policy. 2024; .

PMID: 39623116 DOI: 10.1007/s40258-024-00932-x.

Exploring the relationship between condition severity and health-related quality of life in people with haemophilia A across Europe: a multivariable analysis of data from the CHESS II study.

Ferri Grazzi E, Hawes C, Camp C, Hinds D, OHara J, Burke T Health Qual Life Outcomes. 2024; 22(1):58.

PMID: 39075533 PMC: 11288067. DOI: 10.1186/s12955-024-02267-6.

Socioeconomic disadvantage and racial/ethnic disparities in low-risk cesarean birth in California.

Bane S, Mujahid M, Main E, Carmichael S Am J Epidemiol. 2024; 194(1):132-141.

PMID: 38932570 PMC: 11735969. DOI: 10.1093/aje/kwae157.

Economic and Humanistic Burden of Moderate and Severe Hemophilia A and B in Spain: Real-World Evidence Insights from the CHESS II Study.

Peral C, De Lossada Juste A, Lwoff N, Espinoza-Camac N, Casado M, Burke T J Health Econ Outcomes Res. 2024; 11(1):122-133.

PMID: 38721331 PMC: 11078526. DOI: 10.36469/001c.92369.

References

Monahan P, Baker J, Riske B, Soucie J . Physical functioning in boys with hemophilia in the U.S. Am J Prev Med. 2011; 41(6 Suppl 4):S360-8. DOI: 10.1016/j.amepre.2011.09.017. View

Donadel-Claeyssens S . Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia. 2006; 12(2):124-7. DOI: 10.1111/j.1365-2516.2006.01202.x. View

Blanchette V, Key N, Ljung L, Manco-Johnson M, van den Berg H, Srivastava A . Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014; 12(11):1935-9. DOI: 10.1111/jth.12672. View

Mulder K, Llinas A . The target joint. Haemophilia. 2004; 10 Suppl 4:152-6. DOI: 10.1111/j.1365-2516.2004.00976.x. View

Liras A, Segovia C, Gaban A . Advanced therapies for the treatment of hemophilia: future perspectives. Orphanet J Rare Dis. 2012; 7:97. PMC: 3551751. DOI: 10.1186/1750-1172-7-97. View

Mihaylova B, Briggs A, OHagan A, Thompson S . Review of statistical methods for analysing healthcare resources and costs. Health Econ. 2010; 20(8):897-916. PMC: 3470917. DOI: 10.1002/hec.1653. View

Knight C . Health economics of treating haemophilia A with inhibitors. Haemophilia. 2005; 11 Suppl 1:11-7. DOI: 10.1111/j.1365-2516.2005.01153.x. View

Iannone M, Pennick L, Tom A, Cui H, Gilbert M, Weihs K . Prevalence of depression in adults with haemophilia. Haemophilia. 2012; 18(6):868-74. DOI: 10.1111/j.1365-2516.2012.02863.x. View

Coughlan D, Yeh S, ONeill C, Frick K . Evaluating direct medical expenditures estimation methods of adults using the medical expenditure panel survey: an example focusing on head and neck cancer. Value Health. 2014; 17(1):90-7. DOI: 10.1016/j.jval.2013.10.004. View

10.

Bohn R, Aledort L, Putnam K, Ewenstein B, Mogun H, Avorn J . The economic impact of factor VIII inhibitors in patients with haemophilia. Haemophilia. 2004; 10(1):63-8. DOI: 10.1046/j.1365-2516.2003.00849.x. View

11.

Lobet S, Hermans C, Lambert C . Optimal management of hemophilic arthropathy and hematomas. J Blood Med. 2014; 5:207-18. PMC: 4207585. DOI: 10.2147/JBM.S50644. View

12.

Kodra Y, Cavazza M, Schieppati A, De Santis M, Armeni P, Arcieri R . The social burden and quality of life of patients with haemophilia in Italy. Blood Transfus. 2014; 12 Suppl 3:s567-75. PMC: 4044804. DOI: 10.2450/2014.0042-14s. View

13.

Johnson K, Zhou Z . Costs of care in hemophilia and possible implications of health care reform. Hematology Am Soc Hematol Educ Program. 2011; 2011:413-8. DOI: 10.1182/asheducation-2011.1.413. View

14.

Hanley J, McKernan A, Creagh M, Classey S, McLaughlin P, Goddard N . Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia: A United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) guideline. Haemophilia. 2017; 23(4):511-520. DOI: 10.1111/hae.13201. View

15.

Price V, Hawes S, Chan A . A practical approach to hemophilia care in children. Paediatr Child Health. 2008; 12(5):381-3. PMC: 2528710. DOI: 10.1093/pch/12.5.381. View

16.

Cassis F, Querol F, Forsyth A, Iorio A . Psychosocial aspects of haemophilia: a systematic review of methodologies and findings. Haemophilia. 2011; 18(3):e101-14. DOI: 10.1111/j.1365-2516.2011.02683.x. View

17.

OHara J, Hughes D, Camp C, Burke T, Carroll L, Garcia Diego D . The cost of severe haemophilia in Europe: the CHESS study. Orphanet J Rare Dis. 2017; 12(1):106. PMC: 5452407. DOI: 10.1186/s13023-017-0660-y. View

18.

Soucie J, Wang C, Siddiqi A, Kulkarni R, Recht M, Konkle B . The longitudinal effect of body adiposity on joint mobility in young males with Haemophilia A. Haemophilia. 2011; 17(2):196-203. DOI: 10.1111/j.1365-2516.2010.02400.x. View

19.

Konkle B, Ebbesen L, Erhardtsen E, Bianco R, Lissitchkov T, Rusen L . Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost. 2007; 5(9):1904-13. DOI: 10.1111/j.1538-7836.2007.02663.x. View

20.

Manco-Johnson M, Soucie J, Gill J . Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. Blood. 2017; 129(17):2368-2374. PMC: 5409445. DOI: 10.1182/blood-2016-02-683169. View